Macular Degeneration: The Leading Cause of Age
... central vision. The macula is used for reading, driving and recognizing people’s faces. Macular degeneration causes the center of your vision to blur or distort while the side or peripheral vision remains unaffected. It is generally related to the aging process, and is the leading cause of blindness ...
... central vision. The macula is used for reading, driving and recognizing people’s faces. Macular degeneration causes the center of your vision to blur or distort while the side or peripheral vision remains unaffected. It is generally related to the aging process, and is the leading cause of blindness ...
FOI1808 Attachment 5 - Heart of England NHS Foundation Trust
... amount and distribution of fluid in the retina. Treatment The treatment for wet age-related macular degeneration is by an injection of a drug called Lucentis. This treatment is aimed at sealing or stopping the leakage, getting rid of the choroidal neovascularisation and preventing further retinal da ...
... amount and distribution of fluid in the retina. Treatment The treatment for wet age-related macular degeneration is by an injection of a drug called Lucentis. This treatment is aimed at sealing or stopping the leakage, getting rid of the choroidal neovascularisation and preventing further retinal da ...
GUIDANCE MANUAL FOR ASSURING QUALITY OF TRASTUZUMAB NATIONAL INSTITUTE OF BIOLOGICALS
... The innovator product of trastuzumab is a humanized IgGl kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2 (Figure – 2). Trastuzumab is produced by recombinant DNA technology in a mammalian ce ...
... The innovator product of trastuzumab is a humanized IgGl kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2 (Figure – 2). Trastuzumab is produced by recombinant DNA technology in a mammalian ce ...
Sights set on the eye - Bayer research Magazine
... leads to blindness in most cases. But although wet AMD can still not be cured today, current treatments involving an injection into the patient’s eye several times a year are now able to delay or even stop progression of the disease. The Bayer research team headed up by Deeg is now looking for new a ...
... leads to blindness in most cases. But although wet AMD can still not be cured today, current treatments involving an injection into the patient’s eye several times a year are now able to delay or even stop progression of the disease. The Bayer research team headed up by Deeg is now looking for new a ...
Prevention and treatment of age‐related macular degeneration
... ■ THERAPY REVIEW l Age-related macular degeneration ...
... ■ THERAPY REVIEW l Age-related macular degeneration ...
See Important Disclosures and Disclaimers at the end of this report
... (1) It avoids the use of propylene glycol, which has been associated with renal and cardiac side effects and has previously limited the use of the compound in higher quantities. (2) It uses Captisol® technology, which increases the stability of the product, enabling longer administration durations ...
... (1) It avoids the use of propylene glycol, which has been associated with renal and cardiac side effects and has previously limited the use of the compound in higher quantities. (2) It uses Captisol® technology, which increases the stability of the product, enabling longer administration durations ...
Inertly labeled monoclonal antibodies for PET and optical imaging
... Using mAbs as delivery vehicles of toxic agents is one of the most promising applications in antibody therapy. During the earliest mAb research this approach was tested because of the initial lack of successes with naked therapeutic murine mAbs. Delivery of toxic payloads can be divided in three cat ...
... Using mAbs as delivery vehicles of toxic agents is one of the most promising applications in antibody therapy. During the earliest mAb research this approach was tested because of the initial lack of successes with naked therapeutic murine mAbs. Delivery of toxic payloads can be divided in three cat ...
Advances In Ophthalmology
... many forms of cancer – is also one of the medications used intravitreally as an off-label treatment for selected retinal diseases including wet AMD. Dr. Kiss, in collaboration with Ronald G. Crystal, MD, Chairman of Genetic Medicine at Weill Cornell Medicine, and his team have developed an ocular ge ...
... many forms of cancer – is also one of the medications used intravitreally as an off-label treatment for selected retinal diseases including wet AMD. Dr. Kiss, in collaboration with Ronald G. Crystal, MD, Chairman of Genetic Medicine at Weill Cornell Medicine, and his team have developed an ocular ge ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... Abstract: We describe a 85 year old, male patient who attended our OPD with profused swelling of the left eye associated with loss of vision for the past 4 months. He gave no history of trauma, no history of fever and swelling is not associated with pain. The mass was profusedly large measuring 40 c ...
... Abstract: We describe a 85 year old, male patient who attended our OPD with profused swelling of the left eye associated with loss of vision for the past 4 months. He gave no history of trauma, no history of fever and swelling is not associated with pain. The mass was profusedly large measuring 40 c ...
Avastin : EPAR - Scientific Discussion
... Since its introduction by Heidelberger in 1957, 5-fluorouracil (5-FU) has been the standard agent used in the therapy of CRC, and is the benchmark against which all other therapy is measured. These agents have been developed in many different schedules of administration. Modulation of 5-FU anticance ...
... Since its introduction by Heidelberger in 1957, 5-fluorouracil (5-FU) has been the standard agent used in the therapy of CRC, and is the benchmark against which all other therapy is measured. These agents have been developed in many different schedules of administration. Modulation of 5-FU anticance ...
AVEO and Astellas Announce Submission of New Drug Application
... “potential,” “could,” “should,” “seek,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements ab ...
... “potential,” “could,” “should,” “seek,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements ab ...
CDR/04/05 South Essex Cancer Network Final Report
... There have always been robust processes to oversee the management of new drugs in cancer treatment in South Essex. Currently this role is undertaken by the SECN Chemotherapy Board. The agenda/work programme for the group is driven by the two acute trusts Drug and Therapeutics Committees within the n ...
... There have always been robust processes to oversee the management of new drugs in cancer treatment in South Essex. Currently this role is undertaken by the SECN Chemotherapy Board. The agenda/work programme for the group is driven by the two acute trusts Drug and Therapeutics Committees within the n ...
investigators in cancer research and treatment
... that stored data prospectively from all patients being treated with a new drug, even after gaining FDA approval. Doing so would essentially create an evidence-based system where the next patient to be treated would have a better chance of receiving the optimal treatment because of information in the ...
... that stored data prospectively from all patients being treated with a new drug, even after gaining FDA approval. Doing so would essentially create an evidence-based system where the next patient to be treated would have a better chance of receiving the optimal treatment because of information in the ...
Pharmacotherapy for Radiation Retinopathy
... has been shown to be effective in improving visual acuity and decreasing macular edema in a number of case reports with short follow-up.46,47 Several case series have shown mixed results, with patients showing only modest improvements. Mason et al48 reported that in 10 patients treated with bevacizu ...
... has been shown to be effective in improving visual acuity and decreasing macular edema in a number of case reports with short follow-up.46,47 Several case series have shown mixed results, with patients showing only modest improvements. Mason et al48 reported that in 10 patients treated with bevacizu ...
14 - Ynet
... Disease- and patient-specific risk factors may also contribute to the risk of chemotherapy-associated venous thromboembolic disease. In a study of 3003 patients receiving at least one cycle of chemotherapy, symptomatic VTE occurred in 1.9 percent over a median follow-up of 2.4 months, or a rate of 0 ...
... Disease- and patient-specific risk factors may also contribute to the risk of chemotherapy-associated venous thromboembolic disease. In a study of 3003 patients receiving at least one cycle of chemotherapy, symptomatic VTE occurred in 1.9 percent over a median follow-up of 2.4 months, or a rate of 0 ...
Estimating changes in overall survival using progression
... is a critical factor in determining whether or not the treatment is approved by NICE (National Institute for Clinical Excellence). The aim of this study is to attempt to determine how many months it would be expected that a new drug will add to overall survival times for metastatic cancer given that ...
... is a critical factor in determining whether or not the treatment is approved by NICE (National Institute for Clinical Excellence). The aim of this study is to attempt to determine how many months it would be expected that a new drug will add to overall survival times for metastatic cancer given that ...
Cartilage And Nutriceutical Update
... four phase 11 protocols that are under wav to assess the safety and efficacy of shark cartilage for the treatment of cancer. These protocols include: Cartilage Technologies, Inc., phase II assessment of shark cartilage brand Cartilade® in advanced cancer 1993, Simone phase II studies with shark cart ...
... four phase 11 protocols that are under wav to assess the safety and efficacy of shark cartilage for the treatment of cancer. These protocols include: Cartilage Technologies, Inc., phase II assessment of shark cartilage brand Cartilade® in advanced cancer 1993, Simone phase II studies with shark cart ...
Grand Rounds - University of Louisville Ophthalmology
... University of Louisville Department of Ophthalmology and Visual Sciences ...
... University of Louisville Department of Ophthalmology and Visual Sciences ...
off-label use - Moodle Lille 2
... The reconditioning was done by hospitals, pharmacies, or the practitioners themselves In August 2011, the FDA sends out an alert after clusters of Streptococcus endophthalmitis infections. All were linking to the same pharmacy. ...
... The reconditioning was done by hospitals, pharmacies, or the practitioners themselves In August 2011, the FDA sends out an alert after clusters of Streptococcus endophthalmitis infections. All were linking to the same pharmacy. ...
Catia Angiolini - Congressi AIRO
... Results: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P ! .0002). Median cumulative doxorubicin dose at onset was more than 2,220 mg/m2 for MC versus 480 mg/m2 for AC (P ! .0001, hazard ratio, 5.04). MC patients also experienced less gr ...
... Results: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P ! .0002). Median cumulative doxorubicin dose at onset was more than 2,220 mg/m2 for MC versus 480 mg/m2 for AC (P ! .0001, hazard ratio, 5.04). MC patients also experienced less gr ...
this PDF
... Ruca’s initial indication will be in ovarian cancer patients with a specific genetic mutation called “BRCA+” after these patients have failed three or more treatment options (i.e. a 3L+ drug) Ruca has a superior clinical profile as compared to Lynparza®, the current SOC in 3L+ BRCA+ ovarian cancer R ...
... Ruca’s initial indication will be in ovarian cancer patients with a specific genetic mutation called “BRCA+” after these patients have failed three or more treatment options (i.e. a 3L+ drug) Ruca has a superior clinical profile as compared to Lynparza®, the current SOC in 3L+ BRCA+ ovarian cancer R ...
32-05 CASA Investigators Meeting Paris November 2005
... Pathology material should be available for submission for central review as part of the quality control measures for this protocol. Patients must be accessible for follow-up. Patients must be informed of and agree to data and tissue material transfer and handling, in accordance with national data pr ...
... Pathology material should be available for submission for central review as part of the quality control measures for this protocol. Patients must be accessible for follow-up. Patients must be informed of and agree to data and tissue material transfer and handling, in accordance with national data pr ...
32-05 CASA Investigators Meeting Paris November 2005
... Pathology material should be available for submission for central review as part of the quality control measures for this protocol. Patients must be accessible for follow-up. Patients must be informed of and agree to data and tissue material transfer and handling, in accordance with national data pr ...
... Pathology material should be available for submission for central review as part of the quality control measures for this protocol. Patients must be accessible for follow-up. Patients must be informed of and agree to data and tissue material transfer and handling, in accordance with national data pr ...
(PSD) March 2016 PBAC Meeting
... Direct randomised trials of lipegfilgrastim versus pegfilgrastim – pivotal trials Study 02 BioGeneriX XM22-02: Dose-finding of a fixed dose XM22 in patients with (XM22-02) breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta®, ...
... Direct randomised trials of lipegfilgrastim versus pegfilgrastim – pivotal trials Study 02 BioGeneriX XM22-02: Dose-finding of a fixed dose XM22 in patients with (XM22-02) breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta®, ...
Oxaliplatin (for metastatic colorectal cancer)
... is similar in efficacy as the FOLFIRI regimen but is much more expensive. Therefore, the Committee recommended that the FOLFOX regimen be funded for first-line treatment only in patients who have a contraindication or intolerance to the FOLFIRI regimen. The Committee recommended that the FOLFOX regi ...
... is similar in efficacy as the FOLFIRI regimen but is much more expensive. Therefore, the Committee recommended that the FOLFOX regimen be funded for first-line treatment only in patients who have a contraindication or intolerance to the FOLFIRI regimen. The Committee recommended that the FOLFOX regi ...